International Reference Pricing for the Launch of Cell and Gene Therapies
*/ /*-->*/ /*-->*/ /*-->*/ /*-->*/ /*-->*/ /*-->*/
When it comes to cell and gene therapy, setting the right price isn’t easy. As these therapies target unique and/or rare diseases with high unmet medical need, there aren’t any pricing benchmarks for companies to refer to. Expert Rainer Opgen-Rhein explain the importance of international referencing pricing for the successful launch of a cell or gene therapy.
Price benchmarks play an important role when setting prices for pharmaceutical products. This applies to setting prices for comparative therapies within a country (internal referencing) or setting prices for the same product in other countries. The latter is called international reference pricing (IRP).
In this article we will outline why this benchmark is so important to consider when launching a cell or gene therapy, and what tools can be used to succeed?
